The Spectrum This Research Covers

Stress and anxiety exist along a biological and clinical continuum. At one end are transient stress reactions — the acute HPA axis activation that resolves once the stressor passes. At the other are diagnosable anxiety disorders: generalized anxiety disorder, social anxiety disorder, panic disorder, and others defined by the persistence, severity, and functional disruption of the anxiety response rather than by its presence alone.

Most cannabinoid research in this domain operates at the acute end of the spectrum. Studies expose healthy volunteers to standardized laboratory stressors — simulated public speaking tasks, Trier Social Stress Tests, anticipatory stress paradigms — and measure changes in self-reported anxiety, physiological arousal, or both. These are valid research designs. They measure a real signal. They do not establish efficacy in diagnosed anxiety disorder populations, and the research that could establish that — large-scale, long-duration randomized controlled trials in clinical populations — remains limited across the entire cannabinoid literature.

The most important distinction in this literature

A measurable reduction in acute laboratory-induced anxiety is not the same finding as evidence of efficacy in chronic anxiety disorders. Both findings are meaningful. They answer different questions, have different clinical implications, and require different evidence standards to establish. This distinction must be maintained across every study discussed in this article.

CBG: The Archive's Primary Research Focus

CBG
Cannabigerol — Founding Research Compound
Tier 1 — Human Trial

The Cuttler et al. (2024) randomized controlled trial is the first published human trial of CBG's acute effects on stress and anxiety. The trial used a double-blind, placebo-controlled crossover design with 34 healthy adults, a single 20mg oral dose, and validated self-report measures at 20, 45, and 60 minutes post-dose. Statistically significant reductions in both anxiety and stress were observed at all three time points compared to placebo.

Participants did not report intoxication at the dose examined. Cognitive performance remained stable — and the trial found an unexpected statistically significant improvement in verbal word recall, a finding the lead author explicitly flagged for replication before strong conclusions are drawn.

This is a well-designed acute trial in a healthy adult population. It establishes a meaningful human signal. It does not establish efficacy in diagnosed anxiety disorder populations, does not address chronic dosing, and does not measure cortisol or other biological stress markers directly. The Stress & Anxiety pillar in this archive is built around CBG specifically because this research trajectory — beginning with the mechanistic rationale in the preclinical literature and now supported by human trial data — is what preceded and shaped this company.

CBD: The Richer Evidence Base

CBD
Cannabidiol
Tier 1 — Multiple Human Trials

CBD has the most extensive human trial record of any cannabinoid in the stress and anxiety domain. Multiple small randomized controlled trials — using simulated public speaking paradigms and other laboratory stress models — have reported statistically significant reductions in self-reported anxiety compared to placebo. Bergamaschi et al. (2011) found CBD-reduced anxiety in treatment-naïve social anxiety disorder patients during a simulated public speaking task. Crippa et al. (2011) documented anxiety reduction in generalized social anxiety disorder with associated changes in cerebral blood flow in anxiety-relevant brain regions.

CBD's evidence base in this domain is broader than CBG's — more studies, more populations, more designs. It is also subject to the same limitation: most trials are acute, most samples are small, and long-term randomized controlled trials in diagnosed anxiety disorders remain scarce. The acute signal is consistent and meaningful. The clinical disorder question is less resolved than the volume of research interest might suggest.

THC: Dose-Dependent Complexity

THC
Delta-9-Tetrahydrocannabinol
Tier 1 — Variable Findings

THC's relationship to anxiety is dose-dependent in ways that distinguish it sharply from CBD and CBG. At lower doses, some studies report calming or anxiolytic effects. At higher doses, particularly in susceptible individuals or those without prior cannabis experience, THC can increase anxiety, produce paranoia, and heighten HPA axis reactivity rather than reduce it. Bhattacharyya et al. (2010) documented opposing effects of THC and CBD on anxiety-relevant brain regions, with THC increasing and CBD reducing activation in areas including the amygdala and anterior cingulate cortex.

THC is not a focus of this archive's research pillar. It is included here because understanding its dose-dependent anxiety profile helps illustrate why cannabinoid research findings cannot be generalized across compounds without careful attention to the specific molecule, dose, and population being studied.

The Placebo Response Problem

Anxiety research consistently demonstrates substantial placebo response rates — measurable reductions in self-reported anxiety in participants receiving inert treatments. This is not a sign of methodological failure. It reflects genuine neurobiological effects of expectation, context, and the therapeutic encounter itself, all of which are active in anxiety states.

What it means for interpreting cannabinoid anxiety research is that statistically significant effects must be evaluated in terms of whether they exceed placebo response meaningfully, not merely whether they achieve statistical significance. The trials described in this article used placebo-controlled designs specifically to address this. Understanding that placebo response is real and substantial — rather than treating it as noise — makes the controlled trial findings more meaningful, not less.

Shared limits across the cannabinoid anxiety literature

Sample sizes in cannabinoid anxiety trials are consistently modest — most published RCTs have enrolled under 50 participants. Trial durations are short — most measure acute effects, not outcomes over weeks or months. Outcome measures rely primarily on self-report, which is valid but limited. Long-duration trials in diagnosed anxiety disorder populations, with biological outcome measures alongside self-report, represent the research frontier the published literature has not yet reached.

This is the accurate state of a field that has produced consistent early signals worth continued investigation — not an established clinical evidence base for anxiety treatment.

What the Landscape Shows

Taken together, the human evidence in this domain describes a consistent acute signal across multiple cannabinoids under controlled laboratory conditions. CBG has one well-designed RCT showing statistically significant acute stress and anxiety reduction in healthy adults. CBD has several small trials showing similar effects across multiple stress paradigms. THC shows dose-dependent variability that makes its anxiety profile the most complex and context-sensitive of the three.

None of these findings establish that cannabinoids treat anxiety disorders. None have been tested in the long-duration, large-sample, disorder-specific trials that clinical efficacy claims require. The research is at an early but productive stage — producing signals consistent enough to sustain scientific investment, preliminary enough to require significant caution about clinical claims.

This archive covers the CBG research trajectory in depth because that is where the founding research investment of this company was made. The CBD evidence base provides essential context for reading the CBG findings proportionately. Both are covered here as honestly as the current literature allows.